The Experts below are selected from a list of 240714 Experts worldwide ranked by ideXlab platform
George D Demetri - One of the best experts on this subject based on the ideXlab platform.
-
nccn task force report management of patients with gastrointestinal stromal tumor gist update of the nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2007Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Jeanyves Blay, Paolo G Casali, Haesun Choi, Christopher L Corless, Maria Debiecrychter, Ronald P Dematteo, David S EttingerAbstract:The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The Standard of Practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
-
nccn task force report optimal management of patients with gastrointestinal stromal tumor gist expansion and update of nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2004Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Haesun Choi, Christopher L Corless, Ronald P Dematteo, Burton L Eisenberg, Christopher D M Fletcher, Robert G Maki, Brian P RubinAbstract:Abstract NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the Standard of Practice has been affected rapidly and dramatically by the introduction of effective molecularly targeted therapy for this disease. There are few examples in modern medicine in which the implementation of new technologies into Practice has so radically and rapidly affected clinical diagnostic strategies and treatments with significant implications for the care of patients. Because of these recent changes, NCCN organized a broad multidisciplinary panel composed of experts in the fields of diagnostic radiology, pathology, molecular diagnostics, surgery, medical oncology, and radiation oncology to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST task force is composed of NCCN faculty and other key experts from North America, comprising the United States and Canada. The purpose of this meeting was to expand on the existing NCCN clinical Practice guidelines for gastrointestinal sarcomas and to identify areas of future research to optimize our understanding and treatment of this disease.
David S Ettinger - One of the best experts on this subject based on the ideXlab platform.
-
nccn task force report management of patients with gastrointestinal stromal tumor gist update of the nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2007Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Jeanyves Blay, Paolo G Casali, Haesun Choi, Christopher L Corless, Maria Debiecrychter, Ronald P Dematteo, David S EttingerAbstract:The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The Standard of Practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
Daniel P Hsu - One of the best experts on this subject based on the ideXlab platform.
-
Standard of Practice embolization of ruptured and unruptured intracranial aneurysms
Journal of NeuroInterventional Surgery, 2013Co-Authors: Athos Patsalides, Todd A Abruzzo, Ketan R Bulsara, Daniel P Hsu, Mahesh V Jayaraman, Sandra Narayanan, Gary Duckwiler, Richard P Klucznik, Michael Kelly, Joshua A HirschAbstract:Since its inception, coil embolization of cerebral aneurysms was designed and approved by the US Food and Drug Administration for aneurysms considered to be high risk for microsurgical clip ligation, but it is now increasingly considered as the first line of treatment. The techniques for endovascular aneurysm treatment have evolved: new devices have been developed that allow treatment of aneurysms with anatomy previously unfavorable for endovascular occlusion, and indications for endovascular treatment have expanded. Nevertheless, intrasaccular coil embolization has become the mainstay of endovascular aneurysm treatment at the present time, and the medical literature demonstrates better outcomes with treatment by coiling than with clipping in specific patient groups.1–3 In a recent scientific statement from the American Heart Association (AHA),4 either endovascular or microsurgical treatment of cerebral aneurysms amenable to treatment was indicated with AHA Class I level of recommendation for ruptured aneurysms and Class IIa for unruptured aneurysms. In both groups the evidence suggests that the benefit of treatment outweighs the risks. A multidisciplinary team experienced in vascular microneurosurgery, neurocritical care and neurointerventional surgery most appropriately applies best techniques to the management of intracranial aneurysms. The Neurovascular Coalition Writing Group has previously published recommendations for training and competence in cerebrovascular intervention with a joint statement.5 The progressive adoption of endovascular techniques for the treatment of the majority of cerebral aneurysms and the availability of new endovascular devices do not necessarily correspond to continuously improving outcomes. A recent study comparing patient outcomes in New York State showed that patient outcomes have not improved significantly over the last decade despite the association of endovascular coiling with better patient outcomes compared with clipping for patients with unruptured intracranial aneurysms (UIAs).6 This finding raises the concern that the quality of endovascular treatment is at a plateau, thus justifying the need …
-
Standard of Practice embolization of spinal arteriovenous fistulae spinal arteriovenous malformations and tumors of the spinal axis
Journal of NeuroInterventional Surgery, 2013Co-Authors: Sandra Narayanan, Todd A Abruzzo, Kristine A Blackham, Ketan R Bulsara, Colin P Derdeyn, Chirag D Gandhi, Joshua A Hirsch, Robert W Hurst, Felipe C Albuquerque, Daniel P HsuAbstract:Spinal vascular malformations include a heterogeneous group of pathological/anatomical entities with congenital and acquired etiologies that induce spinal cord dysfunction, primarily through intradural extramedullary drainage and enlargement of the coronal venous plexus, resulting in venous hypertension and/or a direct mass effect. These lesions are rare, comprising approximately 5% of neurovascular disorders. Clinical manifestations are pain or venous congestive myelopathy, usually in the thoracolumbar spine. This may progress to hemorrhage from vascular thrombosis and necrotizing myelopathy (Foix–Alajouanine syndrome).1 Due to the differing hemodynamics, pathophysiology, and treatment considerations, a thorough knowledge of the various types of spinal dural arteriovenous fistulas (dAVFs) and arteriovenous malformations (AVMs) is essential. The first descriptions of the single coiled dural vessel form of spinal dAVF with intradural extramedullary venous drainage were published by Kendall and Logue in 1977.2 Type I spinal dAVFs (also known as angioma racemosum venosum) are the most common and comprise 56% of all spinal lesions in the spinal vascular malformation database at the University of Toronto.3 They occur nearly 3–4 times as frequently in men. These generally low flow lesions may be further divided into type I-A (single feeder dAVFs) and I-B (≥2 arterial feeders).4 Although they are typically supplied via radicular arteries, anterior spinal artery feeders have also been reported.5 Type II spinal AVMs (also known as angioma racemosum arteriovenosum) are characterized by a compact, glomus-type, totally intramedullary nidus. They have no gender predominance but are symptomatic in younger patients. Type III (juvenile or metameric) spinal AVMs are highly complex intramedullary lesions that frequently extend into the extramedullary, epidural, or even extraspinal compartments. Vascular …
-
Standard of Practice endovascular treatment of intracranial atherosclerosis
Journal of NeuroInterventional Surgery, 2012Co-Authors: Shazam M Hussain, Justin F Fraser, Todd A Abruzzo, Kristine A Blackham, Ketan R Bulsara, Colin P Derdeyn, Chirag D Gandhi, Joshua A Hirsch, Daniel P Hsu, Mahesh V JayaramanAbstract:Background Symptomatic intracranial atherosclerotic disease (ICAD) worldwide represents one of the most prevalent causes of stroke. When severe, studies show that it has a very high risk for recurrent stroke, highlighting the need for effective preventative strategies. The mainstay of treatment has been medical therapy and is of critical importance in all patients with this disease. Endovascular therapy is also a possible therapeutic option but much remains to be defined in terms of best techniques and patient selection. This guideline will serve as recommendations for diagnosis
Robert S Benjamin - One of the best experts on this subject based on the ideXlab platform.
-
nccn task force report management of patients with gastrointestinal stromal tumor gist update of the nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2007Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Jeanyves Blay, Paolo G Casali, Haesun Choi, Christopher L Corless, Maria Debiecrychter, Ronald P Dematteo, David S EttingerAbstract:The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The Standard of Practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
-
nccn task force report optimal management of patients with gastrointestinal stromal tumor gist expansion and update of nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2004Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Haesun Choi, Christopher L Corless, Ronald P Dematteo, Burton L Eisenberg, Christopher D M Fletcher, Robert G Maki, Brian P RubinAbstract:Abstract NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the Standard of Practice has been affected rapidly and dramatically by the introduction of effective molecularly targeted therapy for this disease. There are few examples in modern medicine in which the implementation of new technologies into Practice has so radically and rapidly affected clinical diagnostic strategies and treatments with significant implications for the care of patients. Because of these recent changes, NCCN organized a broad multidisciplinary panel composed of experts in the fields of diagnostic radiology, pathology, molecular diagnostics, surgery, medical oncology, and radiation oncology to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST task force is composed of NCCN faculty and other key experts from North America, comprising the United States and Canada. The purpose of this meeting was to expand on the existing NCCN clinical Practice guidelines for gastrointestinal sarcomas and to identify areas of future research to optimize our understanding and treatment of this disease.
Charles D Blanke - One of the best experts on this subject based on the ideXlab platform.
-
nccn task force report management of patients with gastrointestinal stromal tumor gist update of the nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2007Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Jeanyves Blay, Paolo G Casali, Haesun Choi, Christopher L Corless, Maria Debiecrychter, Ronald P Dematteo, David S EttingerAbstract:The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The Standard of Practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
-
nccn task force report optimal management of patients with gastrointestinal stromal tumor gist expansion and update of nccn clinical Practice guidelines
Journal of The National Comprehensive Cancer Network, 2004Co-Authors: George D Demetri, Robert S Benjamin, Charles D Blanke, Haesun Choi, Christopher L Corless, Ronald P Dematteo, Burton L Eisenberg, Christopher D M Fletcher, Robert G Maki, Brian P RubinAbstract:Abstract NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the Standard of Practice has been affected rapidly and dramatically by the introduction of effective molecularly targeted therapy for this disease. There are few examples in modern medicine in which the implementation of new technologies into Practice has so radically and rapidly affected clinical diagnostic strategies and treatments with significant implications for the care of patients. Because of these recent changes, NCCN organized a broad multidisciplinary panel composed of experts in the fields of diagnostic radiology, pathology, molecular diagnostics, surgery, medical oncology, and radiation oncology to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST task force is composed of NCCN faculty and other key experts from North America, comprising the United States and Canada. The purpose of this meeting was to expand on the existing NCCN clinical Practice guidelines for gastrointestinal sarcomas and to identify areas of future research to optimize our understanding and treatment of this disease.